Back to Journals » Drug Design, Development and Therapy » Volume 4

Eltrombopag – a novel approach for the treatment of chronic immune thrombocytopenic purpura: review and safety considerations

Authors Cook L, Cooper N

Published 29 June 2010 Volume 2010:4 Pages 139—145

DOI https://doi.org/10.2147/DDDT.S8601

Review by Single-blind

Peer reviewer comments 3


Lucy Cook, Nichola Cooper

Department of Haematology, Imperial Health Care NHS Trust, Hammersmith Hospital, London, UK

Abstract: Eltrombopag is one of a number of novel agents recently developed for use in the treatment of patients with immune thrombocytopenia (ITP). Rather than preventing destruction of platelets, these agents increase the production of platelets, presumably overwhelming the immune system resulting in normal platelet counts in individuals refractory to or dependent on other therapies. These treatments are well tolerated and in randomized controlled trials show an improvement in platelet counts and a reduction in bleeding in refractory patients. This article summarizes the development of this new class of drug and evaluates the safety and efficacy of eltrombopag in patients with ITP.
Keywords: eltrombopag, immune thrombocytopenic purpura, thrombopoietin

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]